ahlam1399
09-23-2015, 07:41 PM
Steep discounts help biotech drug copies gain ground in Europe
LONDON, Sept 23 (Reuters) - Cut-price versions of expensive biotech ***** are gaining ground in Europe, following surprisingly steep price discounts offered on the first copy of a complex antibody medicine for rheumatoid arthritis and Crohn's disease.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4a19a827/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=kewfP36oKiY:xuve8uARyjY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=kewfP36oKiY:xuve8uARyjY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=kewfP36oKiY:xuve8uARyjY:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=kewfP36oKiY:xuve8uARyjY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=kewfP36oKiY:xuve8uARyjY:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/kewfP36oKiY
LONDON, Sept 23 (Reuters) - Cut-price versions of expensive biotech ***** are gaining ground in Europe, following surprisingly steep price discounts offered on the first copy of a complex antibody medicine for rheumatoid arthritis and Crohn's disease.
http://i0.wp.com/reuters.us.feedsportal.com/c/35217/f/654213/s/4a19a827/sc/21/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/companyNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/companyNews?a=kewfP36oKiY:xuve8uARyjY:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/companyNews?i=kewfP36oKiY:xuve8uARyjY:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/companyNews?a=kewfP36oKiY:xuve8uARyjY:V_sGLiPBpWU) http://feeds.feedburner.com/~ff/reuters/companyNews?i=kewfP36oKiY:xuve8uARyjY:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/companyNews?a=kewfP36oKiY:xuve8uARyjY:F7zBnMyn0Lo)
http://feeds.feedburner.com/~r/reuters/companyNews/~4/kewfP36oKiY